Download PDF
Onkologische Welt 2011; 02(01): 43-44
DOI: 10.1055/s-0038-1631204
Serie urologische Onkologie
Schattauer GmbH

Neue Optionen in der metastasierten Situation: Fortschritte in der Therapie des Prostatakarzinoms

Alexander Kretzschmar Dr.
Further Information

Publication History

Publication Date:
03 February 2018 (online)

    Permissions and Reprints

Beim Prostatakarzinom mehren sich nach Ansicht von Prof. Carsten Bokemeyer, Hamburg, die therapeutischen Optionen im fortgeschrittenen Stadium. Dies gilt auch für Männer mit einem hormonrefraktärem Prostatakarzinom, die nach einer Therapie mit Docetaxel eine Progression erleiden, machte er auf einer Fortbildungsveranstaltung deutlich. Hier gab es bislang keine echten therapeutischen Optionen.

 

  • Literatur

  • 1 Andriole et al. Effect of Dutasteride in the Risk of Prostate Cancer. N Engl J Med 2010; 362: 1192-1202.
    CrossrefPubMedGoogle Scholar
  • 2 Bokemeyer C. Tumore des Urogenitaltraktes. Vortrag auf dem 6. Onkologie-Update-Seminar vom 28.-29. Januar. 2011 Berlin:
    PubMedGoogle Scholar
  • 3 Danila DC. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501.
    CrossrefPubMedGoogle Scholar
  • 4 De Bono JS. et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Ann Oncol 2010; 21 Abstract LBA 5.
    CrossrefGoogle Scholar
  • 5 De Bono JS. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 1147-1154.
    CrossrefPubMedGoogle Scholar
  • 6 Fizazi K. et al. A randomized phase III trial of denusomab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2010; 28: 18s Abstract LBA4507.
    Google Scholar
  • 7 Gutt R. et al. Statin use and risk of prostate cancer recurrence in men tretated with radiation therapiy. J Clin Oncol 2010; 28: 2653-2659.
    CrossrefPubMedGoogle Scholar
  • 8 Kantoff et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
    CrossrefPubMedGoogle Scholar
  • 9 Kelly WK. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel, prednisone and bevacizumab in men with metastatic castration-resistant prostate cancer(mCRPC): Survival results of CALGB 90401. J Clin Oncol 2010; 28: 18s Abstract LBA4511.
    Google Scholar
  • 10 Loeb S. et al. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?. J Clin Oncol. 2011; 29 (04) 464-467.
    CrossrefPubMedGoogle Scholar
  • 11 Plekhanov A. et al. Switching from leuprolide to degarelix vs continuous degarelix treatment – effects on longterm PSA control, draft abstract: 4. NEEM-Tagung der European Urologic Association, 10–11. September. 2010
    PubMedGoogle Scholar
  • 12 Ryan CL. et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketokonazol therapy. J Clin Oncol 2010; 28: 1481-1488.
    CrossrefPubMedGoogle Scholar
  • 13 Scher I. et al. Antitumor activity of mdv 3100 in castration-resistant prostate: A phase 1–2 study. Lancet 2010; 375: 1437-1446.
    CrossrefPubMedGoogle Scholar